{"type":"PR","pr":{"number":68,"head":"0ef08ae1751a3df0a0cf51dc3fde984f415f3d3a"},"user":"silvia.vernotico","status":"pending_publish","branch":"cms/2018-09-09-hot-this-week-in-farmaceutica-younger-n-66","collection":"hotthisweek","title":"HOT THIS WEEK IN FARMACEUTICA YOUNGER N.66","description":"Sanofi ha ottenuto dalla Commissione europea l’ok per l’autorizzazione all’immissione in commercio di caplacizumab (ALX-0081), prima terapia specifica per il trattamento della aTTP (porpora trombotica trombocitopenica acquisita).","objects":{"entry":{"path":"site/content/hotthisweek/2018-09-09-hot-this-week-in-farmaceutica-younger-n-66.md","sha":"25cb0d8028144c9b2ca8afdd914ed1b0fcf32d66"},"files":[{"path":"/site/static/img/attachment-1.jpeg","sha":"6bcb45535a03b5c1a11c0dce1e05903f9cd15140"}]},"timeStamp":"2018-11-14T11:01:20.232Z"}